Ortenau Klinikum

The department of Medizinische Klinik II, Hämatologie, Onkologie at Ortenau Klinikum concentrates on blood‑related cancers, including Acute Myeloid Leukemia, Acute lymphoblastic leukemia, Myelodysplastic syndrome, and various lymphomas. Current studies aim to test innovative targeted agents, improve event‑free survival, and reduce treatment‑related toxicity for patients with high‑risk hematologic malignancies.

• Targeted BCL‑2 inhibition combined with standard induction in newly diagnosed AML
• IDH‑mutant specific therapy (ivosidenib/enasidenib) alongside chemotherapy for AML/MDS
• FLT3 inhibition (gilteritinib vs. midostaurin) in frontline AML treatment
• Sequential TKI, chemotherapy, and blinatumomab for Ph+ ALL
• Bispecific antibody (glofitamab) plus polatuzumab vedotin and rituximab for aggressive B‑cell lymphoma

Across the 13 active trials, investigators are evaluating whether these novel approaches can prolong overall survival and achieve deeper molecular remissions, positioning the site as a hub for cutting‑edge hematologic oncology research.

In addition to hematologic work, the clinic conducts extensive studies on solid tumors such as triple‑negative breast cancer, ER+/HER2‑ breast cancer, and advanced high‑grade ovarian, peritoneal, and fallopian tube cancers. The trials focus on integrating immunotherapy, endocrine strategies, and PARP inhibition to improve progression‑free survival and reduce disease recurrence.

• Atezolizumab added to neoadjuvant paclitaxel/carboplatin in triple‑negative breast cancer
• Elacestrant versus standard endocrine therapy in ctDNA‑positive early breast cancer
• Niraparib alone or combined with bevacizumab after chemotherapy for advanced ovarian cancer
• Pembrolizumab followed by consolidation radiotherapy in early‑stage favorable Hodgkin lymphoma
• Dual antibody‑drug conjugate (loncastuximab tesirine) and bispecific antibody (epcoritamab) for relapsed diffuse large B‑cell lymphoma

These investigations aim to establish more effective, less toxic treatment regimens and to expand personalized therapy options for patients across Europe, reinforcing the site’s role in innovative solid‑tumor clinical research.